SELECTIVE ELIMINATION OF EROSIVE CELLS

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

Saved in:
Bibliographic Details
Main Authors SOEDERSTROEM KALLE, GALSGAARD ELISABETH DOUGLAS
Format Patent
LanguageEnglish
Published 16.03.2017
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
Bibliography:Application Number: US201615355087